Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

26.82 -0.47 (-1.74%)

Streaming Delayed Price Updated: 12:24 PM EDT, Jul 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 08, 2022

During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap...

Via Benzinga

Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗

January 14, 2022

A rebound from Monday's lows faded, with the key indexes all down for the week.

Via Investor's Business Daily

Expert Ratings For Beam Therapeutics ↗

January 10, 2022

Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the f...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

Pfizer Continues Its Covid Makeover: What's Next For This Hot Stock? ↗

January 13, 2022

How the pandemic continued a transformation Pfizer says began years ago.

Via Investor's Business Daily

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs ↗

January 10, 2022

Pfizer Inc (NYSE: PFE) and Beam Therapeutics Inc (NASDAQ: BEAM) have announced an exclusive four-year research collaboration focused on in vivo ...

Via Benzinga

Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗

January 10, 2022

The companies hope to cure diseases of the liver, muscle and central nervous system.

Via Investor's Business Daily

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

January 10, 2022

From Pfizer Inc.

Via Business Wire

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗

December 22, 2021

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Via InvestorPlace

Got $1,000? Check Out These 3 Top Biotech Stocks ↗

December 03, 2021

Two big biotechs and one smaller one that could be winners over the long term.

Via The Motley Fool

Being First Is Not Enough For Crispr Therapeutics ↗

November 15, 2021

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 ↗

January 05, 2022

Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE:

Via Benzinga

In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing ↗

November 12, 2021

Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...

Via Benzinga

Cathie Wood's Buying Beam Therapeutics -- Should You? ↗

November 09, 2021

Can this high-flying gene-editing stock keep on climbing for new investors?

Via The Motley Fool

Looking Into Beam Therapeutics's Return On Capital Employed ↗

November 08, 2021

Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a...

Via Benzinga

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology ↗

October 19, 2021

Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease...

Via Benzinga

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week ↗

October 15, 2021

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗

October 19, 2021

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:

Via Benzinga

Beam Therapeutics Stock Flashes Renewed Technical Strength ↗

October 12, 2021

On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before.

Via Investor's Business Daily

Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection ↗

September 27, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce...

Via Benzinga

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data ↗

September 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...

Via Benzinga

Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies ↗

September 23, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing. ...

Via Benzinga

Beam Therapeutics's Return On Capital Employed Insights ↗

September 22, 2021

According to data from Benzinga Pro, during Q2, Beam Therapeutics's (NASDAQ:BEAM) reported sales totaled $6.00 thousand. Despite a 70.57% increase in earnings, the company...

Via Benzinga

Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial ↗

September 15, 2021

The FDA has signed off Magenta Therapeutics Inc's (NASDAQ: MGTA) IND application for MGTA-117. Related Content: Magenta Therapeutics Stock Drops As FDA...

Via Benzinga

Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy? ↗

September 12, 2021

One biotech could have the inside track to profit from a major achievement in CRISPR gene editing.

Via The Motley Fool

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming ↗

September 03, 2021

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Via InvestorPlace

The 3 Best Biotech Stocks to Buy Right Now ↗

August 27, 2021

Let your portfolio reflect your personality.

Via The Motley Fool

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.